Clinical Trial Update: Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial comparing weekly ALTU-238 to daily Nutropin AQ in prepubertal children with growth hormone deficiency, sponsored by Altus Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• ALTU-238 (recombinant human growth hormone)
• Nutropin AQ (somatropin)

Snippet

Sponsor: Altus Pharmaceuticals | Conditions: Growth Hormone Deficiency | Phase 2 | Status: UNKNOWN